Expression and purification of truncated diphtheria toxin, DT386, in Escherichia coli: An attempt for production of a new vaccine against diphtheria

Fatemeh Shafiee, Mohammad Rabbani, Mahdi Behdani, Ali Jahanian-Najafabadi

Abstract


The aim of this study was to produce a recombinant protein consisting of the catalytic and translocation domains of diphtheria toxin for its later application as a vaccine candidate against Corynebacterium diphtheria. To achieve this goal, at first, the amino acid sequence of DT386 was used for prediction of T and B cell epitopes using on-line servers. The DT386 coding sequence was synthesized and subcloned into the NcoI and XhoI sites of pET28a plasmid and recombinant pET28a plasmid was used to transform Escherichia coli BL21 (DE3) host cells. Afterwards, recombinant cells were selected and subjected to induction of expression by 1 mM isopropyl β-D-1-thiogalactopyranoside, (IPTG). Expression of the desired protein was evaluated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting, and finally, the recombinant protein was purified using nickel affinity chromatography. The results of epitope prediction using on-line servers established the ability of DT386 for stimulation of immune system against diphtheria toxin. Restriction digestion of the recombinant plasmids using NcoI and XhoI enzymes confirmed the fidelity of cloning by producing a band of about 1200 bp. SDS-PAGE analysis following induction of expression and also purification step confirmed the expression of the desired protein by showing a band of about 45 kDa. In addition, Western blot analysis using anti-6X-His antibody confirmed the identity of the expected protein. In conclusion, in the present study we amplified and cloned the coding sequence of DT386 fragment, followed by its expression by E. coli BL21 (DE3) cells. Then, the expressed protein was purified and will be used for later studies of evaluation of its immunogenic properties.


Keywords


Diphtheria toxin; DT386; Vaccine candidate; Immunoinformatics

Full Text:

PDF

References


Murphy JR. Corynebacterium diphtheriae. 1996.

Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol. 2000;12:407-413.

Zhang Y, Schulte W, Pink D, Phipps K, Zijlstra A, Lewis JD, et al. Sensitivity of cancer cells to truncated diphtheria toxin. PloS one. 2010;5:e10498.

Ramakrishnan S, Olson T, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 1996;56:1324-1330.

Autran B, Triebel F, Viguier M, Jolivet M, Falmagne P, Debre P. Monoclonal B-cell response to diphtheria toxoid: evidence for cross-reactive epitopes. Immunology. 1987;60:531-538.

Janeway CA, Travers P, Walport M, Shlomchik M. The immune system in health and disease. Immunobiology. 2001. pp. 39.

Cryz SJ, Welkos SL, Holmes RK. Immunochemical studies of diphtherial toxin and related nontoxic mutant proteins. Infect Immun. 1980;30:835-846.

Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open Biol. 2013;3:120139.

Sambrook JF, Russell DW. Molecular cloning. Cold spring Harbor Press, Cold Spring Harbor, NY; 2001. pp. 158-159.

EL‐Manzalawy Y, Dobbs D, Honavar V. Predicting linear B‐cell epitopes using string kernels. J Mol Recognit. 2008;21:243-255.

Doytchinova IA, Guan P, Flower DR. EpiJen: a server for multistep T cell epitope prediction. BMC Bioinformatics. 2006;7:131.

Golshani M, Rafati S, Jahanian-Najafabadi A, Nejati-Moheimani M, Siadat SD, Shahcheraghi F, et al. In silico design, cloning and high level expression of L7/L12-TOmp31 fusion protein of Brucella antigens. ResPharm Sci. 2015;10:436-445.

Jahanian-Najafabadi A, Bouzari S, Oloomi M, Habibi Roudkenar M, Shokrgozar M. Assessment of selective toxicity of insect cell expressed recombinant A1-GMCSF protein toward GMCSF receptor bearing tumor cells. Res Pharm Sci. 2012;7:133-140.

Bazaral M, Goscienski P, Hamburger R. Characteristics of human antibody to diphtheria toxin. Infec Immun. 1973;7:130-136.

Perera V, Corbel M. Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141–157 of fragment A. EpidemiolInfec. 1990;105:457-468.

Rolf JM, Eidels L. Structure-function analyses of diphtheria toxin by use of monoclonal antibodies. Infec Immun. 1993;61:994-1003.

Audibert F, Jolivet M, Chedid L, Alouf J, Boquet P, Rivaille P, et al. Active antitoxic immunization by a diphtheria toxin synthetic oligopeptide. 1981. pp. 593-594.

Sesardic D, Khan V, Corbel MJ. Targeting of specific domains of diphtheria toxin by site-directed antibodies. Microbiol. 1992;138:2197-2203.

Lobeck K, Drevet P, Léonetti M, Fromen-Romano C, Ducancel F, Lajeunesse E, et al. Towards a recombinant vaccine against diphtheria toxin. Infect Immun. 1998;66:418-423.

Lee CW, Lee SF, Halperin SA. Expression and immunogenicity of a recombinant diphtheria toxin fragment A in Streptococcus gordonii. Appl Environ Microbiol. 2004;70:4569-4574.

Savar NS, Jahanian-Najafabadi A, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. J Biotechnol. 2014;175:31-37.

Ouyang J WJ-W, Hong T. Expression, purification and cytotoxicity of diphtheria toxin fragment (DT-386). China Biotechnol. 2004;24:6.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.